Next Generation Sequencing in Liquid Biopsy for Cancer Management

Dr. William Cho｜Chartered Scientist (UK)

    Submit your question here.   

Video Summary

1. Talk about the precision medicine, its goal and how to achieve this goal in oncology.
2. Discuss the identification of genomic alternations in tissue-based approach.
3. Discuss the identification of genomic alternations in liquid-based approach.
4. Compare tissue-based vs liquid-based approach
5. How does this technique provide clinically relevant information at various stages of cancer?
   – Feasibility of liquid biopsies, non-invasive, sufficient samples, allows repeat sampling for longitudinal monitoring, able to capture genomic heterogeneity, overcome situation where solid tumor is inaccessible.
   – In terms of patient’s early diagnosis, treatment options, treatment response
6. Discuss the various aspects of liquid biopsy
7. Describe the EV, CTC and ctDNA in liquid biopsy
8. Explain the concepts of cfDNA, cfDNA and their production and usages
9. Discuss of selection of plasma vs serum
10. Discuss the original study in choosing the centrifuge force in blood preparation
    a- Difference between the NGS technologies of hybrid-capture based NGS and amplicon-based NGS
    b- NGS technologies enable comprehensive genomic profiling (CGP) and its advantage
11. How CGP suit clinical utility rather than RNA sequencing? How these 2 approaches influence patients’ clinical outcome? Relevant clinical experience to be presented.
12. Talk about the two aspects of heterogeneity
13. Discuss about the concordance
14. How liquid biopsy could help cancer patient especially those with B-FAST ALK+
15. Examples of clinical benefits using ctDNA in advanced-stage cancer settings. One or two cases by using NGS for Liquid Biopsy in clinical applications to be presented.
16. Discuss the professional guideline support the liquid biopsy
17. Compare and contrast the common NGS platforms with CDx claims

(Appreciation Acknowledgement: This educational program is supported by Roche Hong Kong Limited.）

• New Era in Precision Medicine – Tumour Agnostic Treatment and Liquid Biopsy
– Dr. Joseph Siu-Kie AU｜Specialist in Clinical Oncology and President of Hong Kong Precision Oncology Society

•“Unlocking the Potential of Precision Medicine” Panel Discussion
– Dr. William CHO｜Chartered Scientist (UK) &
– Dr. Joseph Siu-Kie AU｜ Specialist in Clinical Oncology and President of Hong Kong Precision Oncology Society

For doctors to ask questions

Thank you for your precious time to view the online videos of Unlocking the Potential of Precision Medicine.

You are welcome to send your questions about the new era of precision medicine of liquid biopsy and value of  tumour agnostic cancer therapy after watched the videos.

We will consolidate questions to speakers to answer.

Thank you very much of your interest and kind attention.